NASDAQ · PBYI
Healthcare · Biotechnology
$9.50
Up+$0.32 (+3.41%)
Updated Oct 7, 2026, 4:48 PM
SID Score
6.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · PBYI
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
PBYI closed at $9.50 after 21 trading sessions, up 1.17% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $9.72 | $9.7999 | $9.43 | $9.50 | 322.66K |
| Oct 5, 2026 | $9.45 | $9.78 | $9.33 | $9.67 | 297.63K |
| Oct 2, 2026 | $9.94 | $9.995 | $9.50 | $9.51 | 454.88K |
| Oct 1, 2026 | $9.84 | $10.075 | $9.77 | $9.84 | 518.41K |
| Sep 30, 2026 | $9.85 | $10.10 | $9.74 | $9.93 | 398.97K |
| Sep 29, 2026 | $9.77 | $9.90 | $9.68 | $9.78 | 220.57K |
| Sep 28, 2026 | $9.77 | $9.885 | $9.54 | $9.82 | 245.94K |
| Sep 25, 2026 | $9.90 | $9.90 | $9.65 | $9.77 | 262.07K |
| Sep 24, 2026 | $9.25 | $9.87 | $9.02 | $9.82 | 467.56K |
| Sep 23, 2026 | $9.82 | $9.90 | $9.08 | $9.28 | 475.94K |
| Sep 22, 2026 | $9.65 | $9.98 | $9.57 | $9.82 | 360.72K |
| Sep 21, 2026 | $9.66 | $9.75 | $9.5121 | $9.59 | 217.57K |
| Sep 18, 2026 | $9.52 | $9.66 | $9.44 | $9.60 | 327.07K |
| Sep 17, 2026 | $9.39 | $9.61 | $9.39 | $9.52 | 206.16K |
| Sep 16, 2026 | $9.26 | $9.40 | $9.16 | $9.39 | 188.83K |
| Sep 15, 2026 | $9.15 | $9.3891 | $9.05 | $9.25 | 309.92K |
| Sep 14, 2026 | $9.10 | $9.23 | $9.03 | $9.14 | 256.65K |
| Sep 11, 2026 | $9.26 | $9.2806 | $8.93 | $9.12 | 305.14K |
| Sep 10, 2026 | $9.01 | $9.22 | $8.90 | $9.17 | 173.46K |
| Sep 9, 2026 | $9.31 | $9.446 | $9.01 | $9.05 | 453.61K |
| Sep 8, 2026 | $9.25 | $9.57 | $8.85 | $9.39 | 365.78K |
The latest Smart Investors Daily articles mentioning PBYI.
Company
Market Activity
Research & News
PBYI research
Company profile and research snapshot.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | TD Cowen | Hold | — |
| Feb 28, 2025 | HC Wainwright & Co. | Buy | — |
| Dec 23, 2024 | HC Wainwright & Co. | Buy | — |
| Nov 20, 2024 | HC Wainwright & Co. | Buy | — |
| Nov 8, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 17, 2026
LOS ANGELES, September 17, 2026--Puma Biotechnology has initiated ALISCA®-Lung2, a Phase II trial of alisertib in combination with paclitaxel to treat advanced small cell lung cancer.
Benzinga · Sep 17, 2026
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA®-Lung2) Phase II trial (PUMA-ALI-4202; NCT07465757) of alisertib in combination with
Yahoo · Sep 9, 2026
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SeekingAlpha · Sep 8, 2026
NERLYNX gives PBYI an established revenue stream that can support alisertibâs development into a potential second oncology franchise.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PBYI.
